Subepidermal blistering disorders: A clinical and histopathologic review

Seminars in Cutaneous Medicine and Surgery

Volumn 23, Issue 1, 2004, Pages 10-18

  Kolanko, Ewa ^a   Bickle, Kelly ^a   Keehn, Connie ^a   Glass, L Frank ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLISTER; BULLOUS SKIN DISEASE; CLINICAL FEATURE; DERMATITIS HERPETIFORMIS; DIAGNOSTIC ACCURACY; EPIDERMOLYSIS BULLOSA ACQUISITA; HISTOPATHOLOGY; HUMAN; MUCOUS MEMBRANE PEMPHIGOID; PATHOGENESIS; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PORPHYRIA CUTANEA TARDA; REVIEW;

HUMANS; SKIN DISEASES, VESICULOBULLOUS;

EID: 1642447109     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1085-5629(03)00083-X     Document Type: Review

References (57)

1. Borradori L, Bernard P: Pemphigoid group, in Bolognia JL, Jorizzo JL, Rapini RP, et al (eds): Dermatology. New York, NY, Mosby, 2003, pp 463-477
2. Bickle KM, Roark TR, Hsu S: Autoimmune Bullous Dermatoses: a review. Am Fam Phys 65:1861-1870, 2002
3. Giudice GJ, Emery DJ, Diaz LA: Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 99:243-250, 1992
4. Mueller S, Klaus-Kovtun V, Stanley JR: A 230-kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 92:33-38, 1989
5. Büdinger L, Borradori L, Yee C, et al: Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102:2082-2089, 1998
6. Korman NJ: Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol 134:1137-1141, 1998
7. Trüeb RM, Didierjean L, Fellas A, et al: Childhood bullous pemphigoid. Report of a case with characterization of the targeted antigens. J Am Acad Dermatol 40:338-344, 1999
8. Venning VA, Wojnarowska F: Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 26:585-589, 1992
9. Roujeau JC, Lok C, Bastuji-Garin S, et al: High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 134:465-469, 1998
10. Jordon RE, Beutner EH, Witebsky E, et al: Basement zone antibodies in bullous pemphigoid. JAMA 200:751-756, 1967
11. Cotell S, Robinson ND, Chan LS: Autoimmune blistering skin diseases. Am J Emerg Med 18:288-299, 2000
12. Gammon WR, Briggaman RA, Inman AO, et al: Differentiating anti-lamina lucida and anti-sublamina dense anti-BMZ antibodies by indirect immunoflourescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 82:139-144, 1984
13. Stanley JR, Hawley-Nelson P, Yuspa SH, et al: Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified squamous epithelia. Cell 24:897-903, 1981
14. Labib RS, Anhalt GJ, Patel HP, et al: Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 136:1231-1235, 1986
15. Taylor G, Venning V, Wojnarowska F, et al: Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 29:181-184, 1993
16. Joly P, Roujeau JC, Benichou J, et al: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346:321-327, 2002
17. Briggaman RA, Gammon WR, Woodley DT: Epidermolysis bullosa acquisita of the immunopathological type (dermolytic pemphigoid). J Invest Dermatol 85:79s-84s, 1985 (suppl 1)
18. Kurzhals G, Stolz W, Meurer M, et al: Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol 127:391-395, 1991
19. Gammon WR, Briggaman RA: Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus. Diseases of autoimmunity to type VII collagen. Dermatol Clin 11:535-547, 1993
20. Fine JD: Management of acquired bullous skin diseases. N Engl J Med 333:1475-1484, 1995
21. Mooney E, Falk RJ, et al: Studies on complement deposits in epidermolysis bullosa acquisita and bullous pemphigoid. Arch Dermatol 128:58-60, 1992
22. Mutasim DF, Anhalt GJ: Bullous diseases in the elderly. Clin Geriatr Med 18:43-58, 2002
23. Woodley DT, Briggaman RA, O'Keefe EJ, et al: Identification of the skin basement membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 310:1007-1013, 1984
24. Herron MD, Zone JJ: Dermatitis herpetiformis and linear IgA bullous dermatosis, in Bolognia JL, Jorizzo JL, Rapini RP, et al (eds): Dermatology. New York, NY, Mosby, 2003, pp 479-489
25. Sardy M, Karpati S, Merkl B, et al: Epidermal transglutaminase (T Gase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 195:747-757, 2002
26. Hall RP, Lawley TJ: Characterization of circulating and cutaneous IgA immune complexes in patients with dermatitis herpetiformis. J Immunol 135:1760-1765, 1985
27. Reunala T, Collin P: Diseases associated with dermatitis herpetiformis. Br J Dermatol 136:315-318, 1997
28. Sigurgeirsson B, Agnarsson B, Lindelof B: Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 308:13-15, 1994
29. Fitzpatrick TB, Johnson RA, Wolff K, et al: Color Atlas and Synopsis of Clinical Dermatology: Common & Serious Diseases (ed 4). New York, NY, McGraw-Hill, Medical Publishing Division, 2001
30. Kelly SE, Frith PA, Millard PR, et al: A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol 119:161-170, 1988
31. Zone JJ, Taylor TB, Meyer LJ, et al: The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 110:207-210, 1998
32. Hashimoto T, Ishiko A, Shimizu H, et al: A case of linear IgA bullous dermatosis with IgA and antitype VII collagen autoantibodies. Br J Dermatol 134:336-339, 1996
33. Zone JJ, Taylor TB, Kadunce DP, et al: Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear IgA bullous dermatosis. J Clin Invest 85:812-820, 1990
34. Chaffins ML, Collison D, Fivenson DP: Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 28:998-1000, 1993
35. Egan CA, Lazarova Z, Darling TN, et al: Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine 82:177-186, 2003
36. Yunis JJ, Mobini N, Yunis EJ, et al: Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc Natl Acad Sci USA 91:7747-7751, 1994
37. Fleming TE, Korman NJ: Cicatricial pemphigoid. J Am Acad Dermatol 43:571-591, 2000
38. Lever WF: Pemphigus. Medicine 32:1-123, 1953
39. Van der Werf PJ: Ocular pemphigus. Opthalmologica 152:547-552, 1966
40. Kelly SE, Wojnarowsa F: The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 118:31-40, 1988
41. Domloge-Hultsch N, Anhanlt GJ, Gammon WR, et al: Antiepiligrin cicatricial pemphigoid: a subepithelial bullous disorder. Arch Dermatol 130:1521-1529, 1994
42. Shornick JK: Pregnancy dermatoses, in Bolognia JL, Jorizzo JL, Rapini RP, et al (eds): Dermatology. New York, NY, Mosby, 2003, pp 425-432
43. Shornick JK, Black MM: Fetal risks in herpes gestationis. J Am Acad Dermatol 26:63-68, 1992
44. Shornick JK: Herpes gestationis. Dermatol Clin 11:527-533, 1993
45. Shornick JK, Meek TJ, Nesbitt LT, et al: Herpes gestationis in blacks. Arch Dermatol 120:511-513, 1984
46. Shornick JK, Black MM: Secondary autoimmune diseases in herpes gestationis (pemphigoid gestationis). J Am Acad Dermatol 26:563-566, 1992
47. Yancey KB: Herpes gestationis. Dermatol Clin 8:727-735, 1990
48. Shornick JK: Dermatoses of Pregnancy. Semin Cutan Med Surg 17:172-181, 1998
49. Kroumpouzos G: Dermatoses of pregnancy. J Am Acad Dermatol 45:1-19, 2001
50. Mutasim DF, Adams BB: Immunofluorescence in dermatology. J Am Acad Dermatol 45:803-822, 2001
51. Murphy GM: Porphyria, in Bolognia JL, Jorizzo JL, Rapini RP, et al (eds): Dermatology. New York, NY, Mosby, 2003, pp 679-690
52. Elder GH: Porphyria cutanea tarda. Semin Liver Dis 18:67-75, 1998
53. Zaneta J, Bulaj JD, Phillips RS, et al: Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95:1565-1571, 2000
54. Robinson-Bostom L, DiGiovanna JJ: Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol 43:975-986, 2000
55. Timonen K, Kariniemi A, Niemi K, et al: Vascular changes in erythropoietic protoporphyria: Histopathologic and immunohistochemical study. J Am Acad Dermatol 43:489-497, 2000
56. Fracanzani AL, Taioli E, Sampietro M, et al: Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 35:498-503, 2001
57. McAlister F, McClean K, Hamilton PG, et al: Human immunodeficiency virus infection and porphyria cutanea tarda: Coexistence of risk factors or causative association? Clin Infect Dis 20:348-351, 1995